Recent Updates
Recently added Catalysts
ATRC Positive Sentiment

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

Tuesday, August 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AtriCure, Inc. (Nasdaq: ATRC) announced its participation in the 2026 Wells Fargo Health Care Conference. The company's management will engage in a fireside chat scheduled for September 8, 2026, at 10:15 a.m. Eastern Standard Time. This event underscores AtriCure's commitment to transparency and stakeholder engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • AtriCure is recognized as a leading innovator in surgical treatments.
  • Participation in the 2026 Wells Fargo Health Care Conference highlights company visibility.
  • Management's engagement in a fireside chat indicates proactive communication with stakeholders.

Full Press Release Details

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a

Frequently Asked Questions

When will AtriCure participate in the conference?

AtriCure will participate in the conference on September 8, 2026.

What is the focus of AtriCure's innovations?

AtriCure focuses on surgical treatments for atrial fibrillation and pain management.

What time is AtriCure's fireside chat scheduled?

The fireside chat is scheduled for 10:15 a.m. Eastern Standard Time.

Where is AtriCure based?

AtriCure is based in Mason, Ohio.

ShareAdd on Google
Tags: ATRC Viatris Investor Conferences Healthcare AtriCure Wells Fargo Health Care Conference atrial fibrillation surgical treatments
Last updated: Aug 25, 2026

Biotech snapshot

Cash runway
$168M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AtriCure Bipolar SystemPhase 3
Atrial Fibrillation →